New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart... GlobeNewswire
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on DXR
    Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
    8:00a ET April 1 '24 GlobeNewswire
    Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24GlobeNewswireApril 01, 2024

    Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation(Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American College of Cardiology (ACC.24) at the Georgia World Congress Center in Atlanta, GA, April 6 - 8, 2024.

    "ACC.24 is considered the premier cardiology exposition in the Americas, offering a prime opportunity for Daxor to broaden its reach within the entire cardiovascular community," said Michael Feldschuh, Daxor's CEO and President. "This conference presents an ideal platform for engaging with healthcare providers for whom effective volume management poses a significant challenge. Our blood volume analysis (BVA) technology provides 98% accurate, actionable data to optimize treatment plans and personalize care, improving outcomes while reducing duration and cost of care."

    The Company will be exhibiting at Booth #2312.

    Register for the event HERE.

    About American College of Cardiology

    The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards, and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at www.ACC.org.

    About Daxor Corporation

    Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100(R) (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology HERE.

    Forward-Looking Statements

    Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Relations Contact:Bret ShapiroSr. Managing Partner, CORE IR516-222-2560brets@coreir.com

    COMTEX_450172590/2010/2024-04-01T08:00:37

    Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation(Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American College of Cardiology (ACC.24) at the Georgia World Congress Center in Atlanta, GA, April 6 - 8, 2024.

    "ACC.24 is considered the premier cardiology exposition in the Americas, offering a prime opportunity for Daxor to broaden its reach within the entire cardiovascular community," said Michael Feldschuh, Daxor's CEO and President. "This conference presents an ideal platform for engaging with healthcare providers for whom effective volume management poses a significant challenge. Our blood volume analysis (BVA) technology provides 98% accurate, actionable data to optimize treatment plans and personalize care, improving outcomes while reducing duration and cost of care."

    The Company will be exhibiting at Booth #2312.

    Register for the event HERE.

    About American College of Cardiology

    The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards, and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at www.ACC.org.

    About Daxor Corporation

    Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100(R) (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology HERE.

    Forward-Looking Statements

    Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Relations Contact:Bret ShapiroSr. Managing Partner, CORE IR516-222-2560brets@coreir.com

    COMTEX_450172590/2010/2024-04-01T08:00:37

    DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORU...
    8:00a ET April 15 '24 GlobeNewswire
    Daxor Corporation Announces New Hospital Account at Leading Chicago H...
    8:00a ET April 10 '24 GlobeNewswire
    Daxor Corporation to Exhibit at the American College of Cardiology fo...
    8:00a ET April 1 '24 GlobeNewswire
    Daxor Corporation Acquires Volumex(R) and Megatope(R) From Its Existi...
    8:00a ET March 25 '24 GlobeNewswire
    Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 F...
    8:00a ET March 22 '24 GlobeNewswire
    Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8...
    2:18p ET March 18 '24 GlobeNewswire
    Daxor Corporation CEO and President Michael Feldschuh Provides Corpor...
    2:18p ET March 18 '24 GlobeNewswire
    Daxor Announces Sales to Three New Hospitals Furthering Expansion of ...
    8:00a ET March 11 '24 GlobeNewswire
    Multi-Center Study Presented by Duke at Heart Failure Therapeutics Co...
    8:00a ET March 8 '24 GlobeNewswire
    Daxor Corporation to Exhibit at the Technology and Heart Failure Ther...
    8:00a ET February 26 '24 GlobeNewswire

    Market data provided by News provided by